These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 8774761)

  • 1. The mechanism of comparable serum cholesterol lowering effects of pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A inhibitor, between once- and twice-daily treatment regimens in beagle dogs and rabbits.
    Fujioka T; Nara F; Shimada Y; Fukushige J; Shimotsu H; Shigehara E; Fukami M; Tsujita Y
    Jpn J Pharmacol; 1996 Apr; 70(4):329-35. PubMed ID: 8774761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of pravastatin on cholesterol metabolism of cholesterol-fed heterozygous WHHL rabbits.
    Harsch M; Gebhardt A; Reymann A; Lang G; Schliack M; Löser R; Braesen JH; Niendorf A
    Br J Pharmacol; 1998 May; 124(2):277-82. PubMed ID: 9641543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of single administration of pravastatin sodium on hepatic cholesterol metabolism in rats.
    Fujioka T; Tsujita Y
    Eur J Pharmacol; 1997 Apr; 323(2-3):223-8. PubMed ID: 9128842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pravastatin sodium, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, decreases serum total cholesterol in Japanese White rabbits by two different mechanisms.
    Miyazaki A; Koga T
    Atherosclerosis; 2002 Jun; 162(2):299-306. PubMed ID: 11996949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol.
    Reihnér E; Rudling M; Ståhlberg D; Berglund L; Ewerth S; Björkhem I; Einarsson K; Angelin B
    N Engl J Med; 1990 Jul; 323(4):224-8. PubMed ID: 2114543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitors of cholesterol biosynthesis increase hepatic low-density lipoprotein receptor protein degradation.
    Ness GC; Zhao Z; Lopez D
    Arch Biochem Biophys; 1996 Jan; 325(2):242-8. PubMed ID: 8561503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pravastatin inhibits cellular cholesterol synthesis and increases low density lipoprotein receptor activity in macrophages: in vitro and in vivo studies.
    Keidar S; Aviram M; Maor I; Oiknine J; Brook JG
    Br J Clin Pharmacol; 1994 Dec; 38(6):513-9. PubMed ID: 7888289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The mechanism of lack of hypocholesterolemic effects of pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in rats.
    Fujioka T; Nara F; Tsujita Y; Fukushige J; Fukami M; Kuroda M
    Biochim Biophys Acta; 1995 Jan; 1254(1):7-12. PubMed ID: 7811749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of cholesterol-lowering on plasma membrane lipids and function.
    Lijnen P; Echevaría-Vázquez D; Petrov V
    Methods Find Exp Clin Pharmacol; 1996 Mar; 18(2):123-36. PubMed ID: 8740244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of pravastatin on plasma and urinary mevalonate concentrations in subjects with familial hypercholesterolaemia: a comparison of morning and evening administration.
    Nozaki S; Nakagawa T; Nakata A; Yamashita S; Kameda-Takemura K; Nakamura T; Keno Y; Tokunaga K; Matsuzawa Y
    Eur J Clin Pharmacol; 1996; 49(5):361-4. PubMed ID: 8866629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of pravastatin in relation to low density lipoprotein receptor activity.
    Hayashi H; Naito C; Ito H; Kawamura M; Miyazaki S
    Curr Med Res Opin; 1990; 12(2):100-7. PubMed ID: 2118022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduction of plasma cholesterol levels and induction of hepatic LDL receptor by cerivastatin sodium (CAS 143201-11-0, BAY w 6228), a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, in dogs.
    Yasunobu Y; Hayashi K; Shingu T; Nomura K; Ohkura Y; Tanaka K; Kuga Y; Nomura S; Ohtani H; Nishimura T; Matsuura H; Kajiyama G
    Cardiovasc Drugs Ther; 1997 Sep; 11(4):567-74. PubMed ID: 9358961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative efficacy of once-daily versus twice-daily pravastatin in primary hypercholesterolemia.
    Pan HY; DeVault AR; Brescia D; Willard DA
    Clin Ther; 1991; 13(3):368-72. PubMed ID: 1954638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of pravastatin in patients with primary hypercholesterolemia. II. Once-daily versus twice-daily dosing.
    Hunninghake DB; Mellies MJ; Goldberg AC; Kuo PT; Kostis JB; Schrott HG; Insull W; Pan HY
    Atherosclerosis; 1990 Dec; 85(2-3):219-27. PubMed ID: 2129319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in dogs.
    Davis HR; Pula KK; Alton KB; Burrier RE; Watkins RW
    Metabolism; 2001 Oct; 50(10):1234-41. PubMed ID: 11586500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RG 12561 (dalvastatin): a novel synthetic inhibitor of HMG-CoA reductase and cholesterol-lowering agent.
    Amin D; Gustafson SK; Weinacht JM; Cornell SA; Neuenschwander K; Kosmider B; Scotese AC; Regan JR; Perrone MH
    Pharmacology; 1993; 46(1):13-22. PubMed ID: 8434028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the antiatherosclerotic effects of dihydropyridine calcium channel blocker and HMG-CoA reductase inhibitor on hypercholesterolemic rabbits.
    Takayama M; Matsubara M; Arakawa E; Takada C; Ina Y; Hasegawa K; Yao K
    Vascul Pharmacol; 2007 Apr; 46(4):302-8. PubMed ID: 17197250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of pravastatin sodium alone and in combination with cholestyramine on hepatic, intestinal and adrenal low density lipoprotein receptors in homozygous Watanabe heritable hyperlipidemic rabbits.
    Kuroda M; Matsumoto A; Itakura H; Watanabe Y; Ito T; Shiomi M; Fukushige J; Nara F; Fukami M; Tsujita Y
    Jpn J Pharmacol; 1992 May; 59(1):65-70. PubMed ID: 1507659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pravastatin sodium, an inhibitor of HMG-CoA reductase, decreases HDL cholesterol by transfer of cholesteryl ester from HDL to VLDL in Japanese white rabbits.
    Miyazaki A; Koieyama T; Shimada Y; Kikuchi T; Ito K; Kasanuki N; Koga T
    J Atheroscler Thromb; 2004; 11(1):22-8. PubMed ID: 15067195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Once-daily pravastatin in patients with primary hypercholesterolemia: a dose-response study.
    Jones PH; Farmer JA; Cressman MD; McKenney JM; Wright JT; Proctor JD; Berkson DM; Farnham DJ; Wolfson PM; Colfer HT
    Clin Cardiol; 1991 Feb; 14(2):146-51. PubMed ID: 1904333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.